Abstract
The synthesis and the degradation of gap junctions involve multiple steps that may provide targets for the modulation of intercellular communication. Many studies using cultured cells have examined the effects of inhibitors of protein synthesis, trafficking, or degradation upon connexins. Similarly, activators or inhibitors of various protein kinases have been shown to affect connexin assembly or proteolysis. These studies have helped to elucidate the connexin lifecycle. But, because of their lack of specificity for gap junction proteins, these agents would be expected to have limited therapeutic utility and to produce several deleterious side effects. However, more selective agents are being developed based on specific features of the connexin sequences. Molecular genetic approaches have been used to introduce wild-type connexins to increase intercellular communication in otherwise poorly coupled cells. Decreased intercellular communication may be obtained by application of peptides that mimic the extracellular loops and may prevent docking of hemi-channels. Alternatively, introducing mutant connexins that interfere with the oligomerization/export of endogenous connexins or with channel function by formation of non-functional heteromeric hemi-channels can also reduce intercellular communication.
Current Drug Targets
Title: Gap Junction Synthesis and Degradation as Therapeutic Targets
Volume: 3 Issue: 6
Author(s): Eric C. Beyer and Viviana M. Berthoud
Affiliation:
Abstract: The synthesis and the degradation of gap junctions involve multiple steps that may provide targets for the modulation of intercellular communication. Many studies using cultured cells have examined the effects of inhibitors of protein synthesis, trafficking, or degradation upon connexins. Similarly, activators or inhibitors of various protein kinases have been shown to affect connexin assembly or proteolysis. These studies have helped to elucidate the connexin lifecycle. But, because of their lack of specificity for gap junction proteins, these agents would be expected to have limited therapeutic utility and to produce several deleterious side effects. However, more selective agents are being developed based on specific features of the connexin sequences. Molecular genetic approaches have been used to introduce wild-type connexins to increase intercellular communication in otherwise poorly coupled cells. Decreased intercellular communication may be obtained by application of peptides that mimic the extracellular loops and may prevent docking of hemi-channels. Alternatively, introducing mutant connexins that interfere with the oligomerization/export of endogenous connexins or with channel function by formation of non-functional heteromeric hemi-channels can also reduce intercellular communication.
Export Options
About this article
Cite this article as:
Eric C. Beyer and Viviana M. Berthoud , Gap Junction Synthesis and Degradation as Therapeutic Targets, Current Drug Targets 2002; 3 (6) . https://dx.doi.org/10.2174/1389450023347245
DOI https://dx.doi.org/10.2174/1389450023347245 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Call for Papers in Thematic Issues
New drug therapy for eye diseases
Eyesight is one of the most critical senses, accounting for over 80% of our perceptions. Our quality of life might be significantly affected by eye disease, including glaucoma, diabetic retinopathy, dry eye, etc. Although the development of microinvasive ocular surgery reduces surgical complications and improves overall outcomes, medication therapy is ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Clinical Approaches Toward Tumor Angiogenesis: Past, Present and Future
Current Pharmaceutical Design Ghrelin and Motilin in the Gastrointestinal System
Current Pharmaceutical Design Stability of Genomic Imprinting in Embryonic Stem Cells: Lessons from Assisted Reproductive Technology
Current Stem Cell Research & Therapy Suicidal emperipolesis: a process leading to cell-in-cell structures, T cell clearance and immune homeostasis.
Current Molecular Medicine Effects of Dietary Polyunsaturated Fatty Acids on Mitochondria
Current Pharmaceutical Design Chemomodulating Effects of Flavonoids in Human Leukemia Cells
Anti-Cancer Agents in Medicinal Chemistry Metallic Colloid Nanotechnology, Applications in Diagnosis and Therapeutics
Current Pharmaceutical Design Fanconi Anemia Proteins, DNA Interstrand Crosslink Repair Pathways, and Cancer Therapy
Current Cancer Drug Targets Melatonin Therapy of Pediatric Sleep Disorders: Recent Advances, Why it Works, Who are the Candidates and How to Treat
Current Pediatric Reviews Renal Development: A Complex Process Dependent on Inductive Interaction
Current Pediatric Reviews Glucose-6-Phosphate Dehydrogenase Deficiency: Disadvantages and Possible Benefits
Cardiovascular & Hematological Disorders-Drug Targets Natural and Synthetic Furanocoumarins as Treatment for Vitiligo and Psoriasis
Current Drug Therapy Nuclear Hormone Receptor Signals as New Therapeutic Targets for Urothelial Carcinoma
Current Cancer Drug Targets Analysis of Four Types of Leukemia Using Gene Ontology Term and Kyoto Encyclopedia of Genes and Genomes Pathway Enrichment Scores
Combinatorial Chemistry & High Throughput Screening De-Risking Bio-therapeutics for Possible Drug Interactions Using Cryopreserved Human Hepatocytes
Current Drug Metabolism In vivo Evaluation and Alzheimer’s Disease Treatment Outcome of siRNA Loaded Dual Targeting Drug Delivery System
Current Pharmaceutical Biotechnology Identification of Novel Anti-inflammatory Agents from Ayurvedic Medicine for Prevention of Chronic Diseases: “Reverse Pharmacology” and “Bedside to Bench” Approach
Current Drug Targets Substance Abuse and Movement Disorders
Current Drug Abuse Reviews Cellular Senescence as a Target in Cancer Control
Current Cancer Therapy Reviews GLP-1 Receptor Agonists and Type 1 Diabetes - Where Do We Stand?
Current Pharmaceutical Design